GGrantIndex
← Leaderboards

Sean S Park

Mayo Clinic Rochester

$1,787,171
Attributed
$4,810,222
Total exposure
4
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY201625
$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$4,810,222 · 4

By mechanism

R01$4,446,940 · 3
R21$363,282 · 1

Top collaborators

Most similar at Mayo Clinic Rochester

Same institution · by research overlap

Others in their field

Top investigators on “Tumor

Research focus

TumorSignal TransductionCellsBloodImmunotherapyRadiation TherapyT-LymphocyteImmuneImmune Checkpoint InhibitorCd8-Positive T-LymphocytesProgrammed Cell Death Protein 1Operative Surgical ProceduresPhase Ii Clinical TrialsProgrammed Cell Death Ligand 1Novel TherapeuticsPartial ResponseProgression-Free SurvivalsMediatingInflammatoryNeoantigensInvestigationInsightNeoplastic CellCytotoxic

Grant awards (11)

Radiation and dendritic cells to hepatomas to improve immunotherapy response$628,467
R01 · FY2025 · CA · contact PI
Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma$610,890
R01 · FY2025 · CA · contact PI
Radiation and dendritic cells to hepatomas to improve immunotherapy response$612,951
R01 · FY2024 · CA · contact PI
Radiation and dendritic cell combination to improve immunotherapy response in intrahepatic cholangiocarcinoma$610,890
R01 · FY2024 · CA · contact PI
Radiation and dendritic cells to hepatomas to improve immunotherapy response$612,054
R01 · FY2023 · CA · contact PI
Radiation and dendritic cells to hepatomas to improve immunotherapy response$632,389
R01 · FY2022 · CA · contact PI
Overcoming immune checkpoint inhibition with therapeutic plasma exchange and radiotherapy in melanoma$161,411
R21 · FY2022 · CA · contact PI
Overcoming immune checkpoint inhibition with therapeutic plasma exchange and radiotherapy in melanoma$201,871
R21 · FY2021 · CA · contact PI
A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR$244,801
R01 · FY2018 · CA · contact PI
A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR$247,249
R01 · FY2017 · CA · contact PI
A Phase II Evaluation of SABR in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SABR$247,249
R01 · FY2016 · CA · contact PI